Articles citing this paper
Australia’s COVID-19 vaccine journey: progress and future perspectives
James A. Triccas![https://orcid.org/0000-0003-3730-2339](/media/client/orcid_16x16.png)
![https://orcid.org/0000-0002-7631-4204](/media/client/orcid_16x16.png)
A
B
C
![]() Professor James Triccas is a bacteriologist who uses a multidisciplinary approach to define immunity to chronic bacterial pathogens and develop new treatments to control infection. He is Professor of Medical Microbiology and Deputy Director of the Sydney Institute Infectious Diseases (Sydney ID) at The University of Sydney. He leads the recently established vaccine consortium comprising The University of Sydney, ExcellGene and Bharat Biotech, supported by the Coalition for Epidemic Preparedness Innovations (CEPI), to develop a broadly protective SARS-CoV-2 vaccine. |
![]() Dr Megan Steain is a virologist with expertise in host-pathogen interactions and using viruses as vectors to address multiple health challenges. She is a senior lecturer in the Infection, Immunity and Inflammation theme within the School of Medical Sciences at The University of Sydney. She has over 20 years’ experience working with pathogenic human viruses, including HIV, SARS-CoV-2, varicella zoster virus, herpes simplex virus-1 and human cytomegalovirus. |
Microbiology Australia 45(1) 27-31 https://doi.org/10.1071/MA24009
Submitted: 17 January 2024 Accepted: 28 February 2024 Published: 15 March 2024